STRS Ohio’s BioXcel Therapeutics BTAI Stock Holding History

STRS Ohio’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250	Closed	-$184K	–	2177
2020 Q4	$184K	Sell	250 -413	-62%	-$322K	﹤0.01%	1763
2020 Q3	$459K	Hold	663	–	–	﹤0.01%	1383
2020 Q2	$561K	Sell	663 -125	-16%	-$81.5K	﹤0.01%	1220
2020 Q1	$281K	Buy	788 +257	+48%	+$92.4K	﹤0.01%	1462
2019 Q4	$124K	Hold	531	–	–	﹤0.01%	1746
2019 Q3	$59K	Buy	531 +431	+431%	+$68K	﹤0.01%	1845
2019 Q2	$17K	Buy	+100	New	+$16.9K	﹤0.01%	2039

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's BTAI Position: Q1 2021 in Review

STRS Ohio sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 250 shares — an estimated $184K sold.

STRS Ohio first reported a position in BTAI in Q2 2019 and held it in 7 quarters. The position peaked at $561K in Q2 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

STRS Ohio reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
STRS Ohio sold 250 BioXcel Therapeutics shares in Q1 2021, an estimated $184K.
STRS Ohio first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 7 quarters.
STRS Ohio's BioXcel Therapeutics position peaked at $561K in Q2 2020.
116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on STRS Ohio's 13F filing for Q1 2021, filed 23 Apr 2021.